Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_assertion type Assertion NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_head.
- NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_assertion description "[Treatment of melanoma-patient-derived TAFs with IL-1?/? significantly enhanced their ability to suppress the proliferation and function of melanoma-specific cytotoxic T cells, and this inhibition was partially attributable to upregulation by IL-1 of COX-2 and the PD-1 ligands PD-L1 and PD-L2 in TAFs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_provenance.
- NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_assertion evidence source_evidence_literature NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_provenance.
- NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_assertion SIO_000772 22850568 NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_provenance.
- NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_assertion wasDerivedFrom befree-2016 NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_provenance.
- NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_assertion wasGeneratedBy ECO_0000203 NP1001893.RAkW0sipH4GI2lEpCJ91QFr32v-FNMip2g9V8WBVBdw8s130_provenance.